MerLion Becomes Singapore’s First Biotech To Reach Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
The company will pursue a Phase III trial for acute otitis media with a compound that is partnered with Novartis’ Alcon.
You may also be interested in...
Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets
Lilly Shifts Gears In China With New Shanghai-based R&D Center
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.